Monte Rosa Therapeutics (NASDAQ: GLUE) net income
Monte Rosa Therapeutics reported a net loss of $38.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $72.7m.
Monte Rosa Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin |
|---|---|---|---|
| 2025 | −$38.6m | — | −31.2% |
| 2024 | −$72.7m | — | −96.1% |
| 2023 | −$135.4m | — | — |
| 2022 | −$108.5m | — | — |
| 2021 | −$74.0m | — | — |
| 2020 | −$35.9m | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Monte Rosa Therapeutics net income compared with its sector
By net income for its latest fiscal year, Monte Rosa Therapeutics ranks 236th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Monte Rosa Therapeutics, −31.2%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 234th | Candel Therapeutics | −$38.2m | — |
| 235th | Sight Sciences | −$38.4m | −49.7% |
| 236th | Monte Rosa Therapeutics | −$38.6m | −31.2% |
| 237th | Lifecore Biomedical | −$38.7m | −30.0% |
| 238th | RxSight | −$38.9m | −29.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Monte Rosa Therapeutics
- How much did Monte Rosa Therapeutics earn in fiscal 2025?
- Monte Rosa Therapeutics reported a net loss of $38.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $72.7m.
- Where does Monte Rosa Therapeutics rank in its sector by net income?
- It ranks 236th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Monte Rosa Therapeutics come from?
- From the annual report (Form 10-K) that Monte Rosa Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Monte Rosa Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Monte Rosa Therapeutics: the Monte Rosa Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.